Novo Nordisk Shares See Further Drop; 'Study Links Ozempic To Higher Risk Of Eye Condition That Can Cause Vision Loss' - STAT News
Novo Nordisk Shares See Further Drop; 'Study Links Ozempic To Higher Risk Of Eye Condition That Can Cause Vision Loss' - STAT News
諾和諾德股價進一步下跌；“研究顯示奧塞米克與一種可能導致視力損失的眼部控件風險更高”的資訊
A new observational study on Wednesday reported for the first time a potential link between Novo Nordisk's GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss.
週三發佈了一項新的觀察性研究，首次報道了諾和諾德公司GLP-1藥物Ozempic和Wegovy與一種可能導致視力喪失的眼部疾病之間的潛在聯繫。
After hearing anecdotes of patients on the diabetes and obesity drugs experiencing nonarteritic anterior ischemic optic neuropathy, or NAION, researchers at Massachusetts Eye and Ear analyzed data from a registry of patients at their institution to see if there was a broad trend.
在聽取有關糖尿病和肥胖藥物患者有非動脈性前下部缺血性視神經病變（NAION）的軼事後，馬薩諸塞州眼科和耳科研究人員分析了來自他們機構病例註冊表的患者數據，以查看是否存在廣泛趨勢。
Among 710 patients with type 2 diabetes, there were 17 cases of NAION in patients prescribed semaglutide (the scientific name of both drugs). This translated to a cumulative...
在710名2型糖尿病患者中，處方塞格魯肽（兩種藥物...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。